CureVac NV (CVAC)
2.685
-0.06
(-2.19%)
USD |
NASDAQ |
Nov 14, 16:00
2.73
+0.04
(+1.68%)
After-Hours: 20:00
CureVac Enterprise Value: 394.66M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 394.66M |
| November 12, 2024 | 424.94M |
| November 11, 2024 | 404.76M |
| November 08, 2024 | 415.97M |
| November 07, 2024 | 413.73M |
| November 06, 2024 | 420.46M |
| November 05, 2024 | 436.16M |
| November 04, 2024 | 386.81M |
| November 01, 2024 | 398.03M |
| October 31, 2024 | 393.54M |
| October 30, 2024 | 407.00M |
| October 29, 2024 | 427.19M |
| October 28, 2024 | 413.73M |
| October 25, 2024 | 395.78M |
| October 24, 2024 | 389.05M |
| October 23, 2024 | 384.57M |
| October 22, 2024 | 395.78M |
| October 21, 2024 | 400.27M |
| October 18, 2024 | 407.00M |
| October 17, 2024 | 411.49M |
| October 16, 2024 | 415.97M |
| October 15, 2024 | 409.24M |
| October 14, 2024 | 411.49M |
| October 11, 2024 | 431.67M |
| October 10, 2024 | 422.70M |
| Date | Value |
|---|---|
| October 09, 2024 | 431.67M |
| October 08, 2024 | 427.19M |
| October 07, 2024 | 447.38M |
| October 04, 2024 | 456.35M |
| October 03, 2024 | 442.89M |
| October 02, 2024 | 451.86M |
| October 01, 2024 | 445.13M |
| September 30, 2024 | 438.40M |
| September 27, 2024 | 451.86M |
| September 26, 2024 | 456.35M |
| September 25, 2024 | 465.32M |
| September 24, 2024 | 494.48M |
| September 23, 2024 | 472.05M |
| September 20, 2024 | 503.45M |
| September 19, 2024 | 516.91M |
| September 18, 2024 | 516.91M |
| September 17, 2024 | 514.67M |
| September 16, 2024 | 512.43M |
| September 13, 2024 | 550.56M |
| September 12, 2024 | 472.05M |
| September 11, 2024 | 458.59M |
| September 10, 2024 | 463.08M |
| September 09, 2024 | 433.92M |
| September 06, 2024 | 393.54M |
| September 05, 2024 | 418.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
189.91M
Minimum
Apr 25 2024
23.53B
Maximum
Dec 09 2020
4.737B
Average
1.624B
Median
Jul 14 2023
Enterprise Value Benchmarks
| BioNTech SE | 8.336B |
| Bayer AG | 10.49B |
| Affimed NV | 30.82M |
| InflaRx NV | 20.31M |
| Immatics NV | 314.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -78.11M |
| Revenue (Quarterly) | 15.54M |
| Total Expenses (Quarterly) | 95.76M |
| EPS Diluted (Quarterly) | -0.3446 |
| Gross Profit Margin (Quarterly) | -182.1% |
| Profit Margin (Quarterly) | -502.5% |
| Earnings Yield | -49.94% |
| Normalized Earnings Yield | -50.45 |